Eptinezumab in Participants With Episodic Cluster Headache — ALLEVIATE

Cluster Headache, Episodic Clinical Trial

Official title:
Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)

Clinical Trial Description

Eligible participants will be randomly assigned to receive treatment, in a blinded manner, two infusions of either eptinezumab or placebo in a cross-over manner during the Placebo-controlled Period and Active Treatment Period of the study. The total duration of the study after randomization is 24 weeks, including a safety follow-up period of 8 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04688775
Study type	Interventional
Source	H. Lundbeck A/S
Contact
Status	Completed
Phase	Phase 3
Start date	December 23, 2020
Completion date	October 5, 2023

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT05084469` - Exploration of Cluster Headache in a PET-MRI Study
	Completed	`NCT04014634` - GON-injection for a Sooner and Better Treatment of Cluster Headache	Phase 4